Menu
Menu
Clonal hematopoiesis of indeterminate potential (CHIP) is an increasingly recognized challenge in liquid biopsy analysis. Somatic variants arising in hematopoietic progenitor cells can appear in cell-free DNA (cfDNA) analyses, mimicking tumor-derived signals and complicating result interpretation. Correctly assigning these variants is critical – both to avoid false tumor calls and to capture CHIP's emerging role as an independent biomarker for cancer risk and outcomes.
MSK-ACCESS® powered with SOPHiA DDM™ incorporates matched white blood cell (WBC) DNA sequencing to systematically distinguish CHIP and germline variants from true tumor-derived signals. In this poster presentation, Florian Klemm shares findings from a multicenter, retrospective study evaluating CHIP detection across different cfDNA analysis approaches in individuals with colorectal, prostate, pancreatic, and breast cancer. This research was conducted in collaboration with Synnovis, UK.
Watch to discover:
Presenter
Florian Klemm, Technical Product Manager Expert Lead, SOPHiA GENETICS, Rolle, Switzerland
Dr. Florian Klemm is a physician-scientist and tumor immunologist with deep expertise in next‑generation sequencing (NGS), liquid biopsy technologies, and translational oncology. As a Technical Product Manager Expert Lead at SOPHiA GENETICS, he drives the product design of decentralized cfDNA NGS solutions. Most notably, he has led the development of MSK‑ACCESS® powered with SOPHiA DDM™ where he led cross‑functional teams spanning assay development, bioinformatics, tertiary annotation, and software.
With more than a decade of research experience across the Ludwig Institute for Cancer Research at the University of Lausanne, Switzerland, Memorial Sloan Kettering Cancer Center, New York, USA and the University of Göttingen, Germany, Florian has an extensive track record applying NGS, multidimensional genomics, spatial tissue analysis, and large‑scale datasets to advance understanding of tumor biology and tumor–immune interactions. His first‑author publication in Cell (2020) highlights his contributions to mapping immune cell states in brain malignancies. He is passionate about bridging clinical insight, high‑throughput technologies, and data‑driven approaches to deliver impactful solutions that improve patient outcomes.
The SOPHiA GENETICS™ Global Precision Medicine Forum returns to ESMO! Join us on October 22nd at 3:00 PM CET at the Novotel Madrid Campo de las Naciones, Madrid, Spain, for its 2026 edition.
The liquid biopsy movement continues. Building on the conversation started by SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) at ASCO 2026, this forum explores how expanding access to liquid biopsy is now translating into clinical action. Join the pioneers driving this transformation as they share real-world insights from routine practice, demonstrate how decentralized testing is shaping patient care, and reveal how the same model is enabling the next generation of precision oncology biomarkers.
Join Pharma and Biotech leaders, oncology KOLs, and diagnostic partners to explore The Liquid Biopsy Movement: From Access to Action, and how it is reshaping the future of cancer care.
Across different sessions, the forum will explore:
Don’t miss this unique opportunity and reserve your spot now!
What began at our inaugural forum in 2024 has since taken shape across the field. SOPHiA GENETICS and the Memorial Sloan Kettering Cancer Center (MSK) return to ASCO to convene leading voices in precision oncology, this time with a singular focus: the liquid biopsy revolution.
This forum traces the journey from a pioneering academic-industry collaboration with MSK to a global movement reshaping how cancer is detected, monitored, and treated.
Topics:
Speakers:
Join SOPHiA GENETICS™ and ARC Regulatory for an exclusive Industry Reception bringing together precision medicine and pharma leaders in Boston on July 21st.
Following our recently announced Master Collaboration Agreement, this event will spotlight our integrated solution for pharma companies across the clinical development lifecycle in Europe, combining ARC's IVDR regulatory expertise with SOPHiA GENETICS' NGS technology and CE-IVD track record.
You’ll hear directly from both teams about key milestones, including the co-development of a Clinical Trial Assay (CTA) designed to accelerate patient recruitment in European clinical trials.
Accelerate with Impact: Expanding Patient Access to Precision Medicine Across the EU
The programme will be followed by a networking reception, offering a unique opportunity to connect with peers and leaders shaping the future of precision medicine.
Reserve your spot today!
El GENOMiCS INSIGHTS Day Panama se llevará a cabo el próximo 30 de julio, en el restaurante Maito. Este encuentro reunirá a expertos, líderes clínicos y profesionales del área de la genómica para explorar los avances más recientes en medicina de precisión y el impacto creciente de las tecnologías genómicas en la práctica clínica. Durante la jornada abordaremos temas clave como la transformación del diagnóstico genómico en Latinoamérica, las nuevas posibilidades clínicas de la biopsia líquida y experiencias reales de implementación en la práctica clínica con la plataforma SOPHiA DDM™. Este espacio también busca fomentar el intercambio de experiencias y la conversación entre profesionales del sector, promoviendo el avance de la medicina genómica en la región. A continuación, encontrará la agenda preliminar del evento.
What: SOPHiA GENETICS Exclusive Networking event
Where: Restaurante Maito
Date: 30 de julio
Time: 18h00-21h:00
18:00 – 18:30
Transformando el diagnóstico genómico en Latinoamérica con SOPHiA GENETICS.
Gabriela Acosta, Sales Executive LATAM, SOPHiA GENETICS
18:30 – 19:00
Expandiendo las posibilidades clínicas con las soluciones de biopsia líquida de SOPHiA GENETICS.
Luna Rodriguez, Subject Matter Expert LATAM, SOPHiA GENETICS
19:00 - 19:30
Biopsia líquida en la práctica clínica: experiencia real con la plataforma SOPHiA DDM™.
July Katherine Rodriguez Ariza, Directora científica, FICMAC
19:30 – 21:00
Dinner & Networking
Discover how SOPHiA DDM™ enables accurate analysis across multiple disease areas – from oncology to inherited disorders
Enjoy a networking environment with your peers and users of SOPHiA DDM™ Platform.
Discuss the future of research and healthcare institutions to harness NGS data for quick, robust, and actionable insights, guiding best decisions.
We are thrilled to be back at the 16th World Clinical Biomarkers & Companion Diagnostics Summit. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
Our team will be happy to see you join our Plenary Talk and our Co-hosted Engager with Myriad Genetics.
Plenary Talk on Tuesday, October 6th, from 5.40 to 6.10 pm.
“The Power of Modular CGP: Enabling Precision Oncology Across Drug Development”
Mike Berger, PhD, Co-Director, Marie Josee & Henry Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Julien Pontis, PhD, Head of CDx & Clinical Diagnostics, SOPHiA GENETICS
Join this session to explore how MSK-IMPACT® Flex powered with SOPHiA DDM™ is reshaping the future of precision medicine. In this session you will:
Understand how a flexible, future-proof CGP infrastructure helps pharma keep pace with an evolving biomarker landscape, and how SOPHiA GENETICS is already delivering this across the drug development continuum through hands-on partnerships with key diagnostic players.
Co-hosted Engager, coupled with a networking dinner, on Tuesday, October 6th from 7.30 to 10.00 pm.
“Pioneering Precision Medicine: A New Model for CDx Development & Commercialization”
In this workshop, we will explore how a groundbreaking industry collaboration is rethinking current CDx approaches through a hybrid model designed for rapid scalability and access in precision medicine.
This is an invitation-only engager session. If you are interested in attending, please contact the Hanson Wade team.
10 June 2026 I 15:00 - 17:00 GST | 7:00 - 9:00 EDT
Join us for an exclusive virtual event bringing together leading oncology experts, healthcare decision-makers, pharmaceutical partners, policy representatives, and key opinion leaders from across the Middle East region.
This high-level session will explore the future of precision medicine and the evolving role of liquid biopsy in transforming cancer care delivery and genomic testing strategies.
At the center of the discussion is the collaboration between SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center, showcasing the successful decentralization of MSK’s renowned genomic assay, MSK-ACCESS™, powered with SOPHiA DDM™ for liquid biopsy applications.
The event will also feature real-world implementation examples and regional perspectives from our local users at M42, an Abu Dhabi-based global healthcare leader, highlighting innovation, scalability, and impact in precision oncology.
Meet our world class line-up of speakers
Dr. Ghassan Abou Alfa, MD, MBA, PhD
Gastrointestinal Medical Oncologist, Memorial Sloan Kettering Cancer Center
Dr. Val Zvereff
Medical Director, M42 Biogenix
Dr. Azza Attia
Head of Clinical Genomics, M42 Biogenix
Dr. Lina Li, MBA
Product Director Solid Tumors & Liquid Biopsy, SOPHiA GENETICS
Dr. Massimo Cerfeda
Regional Director South & East Europe, SOPHiA GENETICS
The second webinar in the Precision Oncology Showcase series, sponsored by SOPHiA GENETICS, will highlight the successful decentralization of MSK-ACCESS® on the SOPHiA DDM™ Platform. We will explore findings from our internal verification study, insights from early adopter sites, and real-world data that demonstrate how our collaboration with Memorial Sloan Kettering Cancer Center (MSK) has overcome decentralization challenges—delivering high analytical concordance with single-site testing.
We are also excited to welcome Leah Thompson, MB (ASCP)CM, Lab Technician at Tennessee Oncology, who will share her experience verifying and implementing MSK-ACCESS® powered by SOPHiA DDM™. She will discuss analytical performance, workflow simplicity, and the ease of integrating the solution into a laboratory setting.
Key Discussion Points:
Learning Objectives:
July 8, 2026 | 1:00PM SGT
Liquid biopsy (LBx) has emerged as a non-invasive genomic profiling approach to guide decision-making and to monitor resistance in cancer, especially when access to tumor tissue is limited. However, one of the key challenges of LBx is distinguishing somatic variants from clonal hematopoiesis (CH)-derived variants, which can occur in biologically relevant genes and confound variant interpretation. In this webinar, Dr. Keller and Dr. Fares (IUCT Oncopole, France) will explore real-world cases where insights from MSK-ACCESS® powered with SOPHiA DDM™ helped inform decisions. The decentralized liquid biopsy solution integrates matched white blood cell (WBC) DNA sequencing to filter out CH and germline variants, increasing confidence in the somatic origin of detected alterations.
By attending this session, you will gain:
June 3, 2026 | 1:00PM SGT
Clinical Genomics at MSK
Michael Berger, Ph.D
Co-Director, Marie Josee & Henry Kravis Center for Molecular Oncology, MSKCC
Dr. Berger’s session will explore the development of MSK-IMPACT and MSK-ACCESS, MSK’s comprehensive genomic profiling andcfDNA analysis programs. These initiatives address the need for large-scale molecular profiling across diverse tumor types. A keyfocus will be the role of matched tumor-normal sequencing in reducing biological false positives, ensuring true somatic variantsare accurately identified while enabling seamless integration of germline analysis. Dr. Berger will also discuss how SOPHiAGENETICS has become a key collaborator, empowering MSK to expand the accessibility of precision oncology globally throughscalable, cloud-based solutions.
Advancing Precision Oncology with a Matched Tumor-Normal Approach: Insights from the Clinic
Anita Bowman, M.S,
Associate Director of Clinical Bioinformatics, MSKCC
Anita Bowman will delve into the clinical applications of MSK-IMPACT and MSK-ACCESS at MSK, illustrating how thesetechnologies meet the personalized needs of patients. Through real-world case studies, she will showcase how a matchedtumor-normal approach has enhanced diagnosis and treatment planning. This methodology not only minimizes false positivesbut also identifies clonal hematopoiesis of indeterminate potential (CHIP) and resistance mechanisms, improving precision intreatment strategies.
Learning Objectives
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.